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Abstract
Background: Heavy menstrual bleeding (HMB) is a common problem affecting approximately 1.5 million women
in England and Wales with a major impact on their physical, emotional, social and material quality of life. It is the
fourth most common reason why women attend gynaecology outpatient clinics and accounts for one-fifth of all
gynaecology outpatient referrals. Initial treatment in primary care is medical - either by means of oral or injected
medication or the levonorgestrel-intrauterine system (Mirena®). If medical treatment fails then surgical treatment
can be offered, either endometrial ablation (EA), which destroys the lining of the cavity of the uterus
(endometrium), or hysterectomy, i.e. surgical removal of the uterus.
While effective, conventional hysterectomy is invasive and carries a risk of complications due to injury to other
pelvic structures. The procedure can be simplified and complications minimised by undertaking a ‘supracervical’
hysterectomy where the cervix is left in situ and only the body of the uterus removed. Recent advances in
endoscopic technologies have facilitated increased use of laparoscopic supracervical hysterectomy (LASH) which
can be performed as a day-case procedure and is relatively easy for the surgeon to learn.
HEALTH (Hysterectomy or Endometrial AbLation Trial for Heavy menstrual bleeding) aims to address the question
‘Is LASH superior to second generation EA for the treatment of HMB in terms of clinical and cost effectiveness?’
Methods/Design: Women aged < 50 years, with HMB, in whom medical treatment has failed and who are eligible
for EA will be considered for trial entry. We aim to recruit women from approximately 30 active secondary care
centres in the UK NHS who carry out both surgical procedures. All women who consent will complete a diary of
pain symptoms from day 1 to day 14 after surgery, postal questionnaires at six weeks and six months after surgery
and 15 months post randomisation. Healthcare utilisation questions will also be completed at the six-week,
six-month and 15-month time-points.
Discussion: Measuring the comparative effectiveness of LASH vs EA will provide the robust evidence required to
determine whether the new technique should be adopted widely in the NHS.
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Background
Heavy menstrual bleeding (HMB) is a common problem
which affects approximately 1.5 million women in
England and Wales. For clinical purposes, HMB is de-
fined as excessive menstrual blood loss which interferes
with the woman’s physical, emotional, social and mater-
ial quality of life (QoL), and which can occur alone or in
combination with other symptoms [1].
The condition accounts for one-fifth of all gynaecology
outpatient referrals and has a major impact on women’s
physical, emotional, social and material QoL. The condi-
tion is initially treated by general practitioners, either by
means of oral or injected medication or insertion of the
levonorgestrel-intrauterine system (Mirena®). If medical
treatment fails, surgical treatment can be offered, either
in the form of endometrial ablation (EA), which destroys
the lining of the cavity of the uterus (endometrium), or
hysterectomy, i.e. surgical removal of the uterus. How-
ever, neither medical treatment nor EA can guarantee
complete resolution of symptoms. Up to 59% of women
on oral drugs [2] and 13.5% of those using the
levonorgestrel-intrauterine system (Mirena) [3] require
surgery within two years, while 19% of women treated
by EA go on to have a hysterectomy for relief of their
symptoms [4].
Hospital Episode Statistics data indicate that a total of
136,921 hysterectomies and 128,434 EAs for HMB were
performed in England and Wales between April 1997
and December 2009 [5]. EA is commonly performed at
present by means of second-generation or non-
hysteroscopic procedures including thermal balloon EA
and bipolar electrode EA (Novasure® (Hologic Inc.)).
The National Institute for Health and Care Excellence
(NICE) guideline on HMB recommends both EA as well
as hysterectomy as options for women with HMB resist-
ant to medical treatment [1], but a significant minority of
women treated with EA are likely need further EA or hys-
terectomy. A recent individual patient data meta-analysis
[6] of results from randomised trials has shown that des-
pite the greater invasiveness, longer hospital stay and
prolonged recovery associated with conventional hysterec-
tomy (removal of the uterus and the cervix), fewer women
are dissatisfied with it in comparison with EA. Addition-
ally, a cost-effectiveness model based on these data also
favoured hysterectomy [7]. A Health Technology Assess-
ment (HTA) evidence synthesis report [8] showed that
one-quarter of all women who undergo EA will require
subsequent gynaecological surgery, with just under one-
fifth requiring hysterectomy. These findings, which are
consistent with those of a relevant Cochrane review [9],
suggest that the optimal surgical treatment for HMB un-
responsive to medical treatment may well be hysterec-
tomy, but its effectiveness needs to be balanced against its
invasiveness and increased short-term and long-term mor-
bidity [4].
Unlike conventional hysterectomy, the more recent ap-
proach of laparoscopic supracervical hysterectomy
(LASH) removes the body of the uterus, which is
responsible for menstrual bleeding, but conserves the cer-
vix and the uterosacral ligament complex. It is minimally
invasive, quick, relatively easy to learn and associated with
low risk of complications, short hospital stay (under 24 h)
and rapid recovery time [10, 11] and could potentially pro-
vide the benefits of a conventional hysterectomy without
its morbidity and prolonged recovery time.
Before this technique is incorporated into routine clin-
ical practice, it is important that it is subjected to robust
evaluation. Authors of two small randomised trials com-
paring LASH with a first-generation EA—endometrial
resection [11]—or second-generation EA—thermal bal-
loon [10]—suggest that LASH could lead to a better
QoL, but have emphasised the need for larger evaluative
studies to confirm this, a view endorsed by the relevant
Cochrane and HTA reviews.
The last decade has seen widespread use of laparo-
scopic techniques in gynaecology due to increased
familiarity with the procedures, more sophisticated in-
struments, better training and greater surgical skill. As
a result of this, LASH could be delivered by most gen-
eral gynaecologists with minimal morbidity to women
who are currently being treated with EA. Advances in
perioperative care also means that, unlike conventional
hysterectomy, hospital stay in women treated by this
procedure may not be any longer than in those receiv-
ing EA.
HEALTH (Hysterectomy or Endometrial AbLation
Trial for Heavy menstrual bleeding) is a multicentre ran-
domised controlled trial (RCT) comparing LASH with
second-generation EA (the current first line surgical
treatment for HMB) in terms of clinical and cost-
effectiveness. The trial is relevant and timely, as a robust
evaluation of this new surgical option will provide
much-needed high-quality evidence to underpin any
decision to offer it as a preferred treatment.
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Methods/Design
Study design
We have designed a multicentre RCT of alternative surgi-
cal treatments for women with HMB. The trial structure
is shown in Fig. 1 (flow diagram). The rationale for our
proposed trial design reflects the uncertainties in the evi-
dence base in this clinical area. EA is a successful treat-
ment in the short term, but as around 20% of women who
fail to benefit from this procedure will need further
treatment such as repeat ablation or hysterectomy, it is
important to address the impact of these events on rela-
tive cost-effectiveness. Conventional hysterectomy (where
the cervix is removed along with the body of the uterus
through an open procedure) is a definitive treatment, but
is also potentially more morbid, with a longer postopera-
tive recovery time. LASH offers the permanence of a con-
ventional hysterectomy by means of a less invasive
procedure with a quick recovery time.
Study population
We aim to recruit women aged < 50 years with HMB
who are eligible for EA from approximately 30 active
secondary care NHS hospitals in the UK which can carry
out both surgical procedures. Discussions at meetings
facilitated by the relevant professional organisation, the
British Gynaecological Endoscopy Society, and an online
survey of members of this Society have confirmed that
Fig. 1 HEALTH flow diagram
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minimal access surgeons from these centres are willing
to randomise women to either option.
Inclusion and exclusion criteria
Inclusion criteria
1. Women aged < 50 years with HMB eligible for EA.
2. Women who are willing to be randomised between
LASH and EA.
Exclusion criteria
1. Women with plans to conceive, endometrial atypia,
abnormal cytology, uterine cavity size > 11 cm, any
fibroids > 3 cm, contradictions for laparoscopic
surgery (e.g. midline lower abdominal incision or
known intrabdominal / pelvic adhesions) and
previous EA.
2. Women who are unable to give informed consent or
complete trial documentation.
Trial interventions
This protocol addresses the comparison of two surgical
operations for HMB: LASH and EA. The surgical proce-
dures have been agreed and standardised by consensus
within the research team and recruiting gynaecologists.
EA will be performed using second-generation tech-
niques under either local or general anaesthetic.
Laparoscopic supracervical hysterectomy (LASH)
LASH involves removal of the upper part of the uterus
or the body by means of keyhole surgery facilitated by
use of morcellation or culdotomy to remove the uterine
corpus. The uterine body contains the endometrial cav-
ity lined with tissue which undergoes cyclic growth and
shedding each month thus causing menstrual bleeding.
Increased access to specialised laparoscopic equipment
and training means that LASH is quick and relatively
easy to learn. It is associated with low morbidity, short
hospital stay (under 24 h) and rapid recovery time.
Unlike conventional total hysterectomy, the cervix is not
removed, thus removing the need for bladder dissection,
extended surgery around the cervix and often disruption
of the uterosacral ligament complex. These extra steps,
necessary for the removal of the cervix, can lead to ser-
ious complications such as injury to the bladder, ureters
and blood vessels. As the cervix is retained, cervical
smears are still required and although most women will
cease to have periods after the procedure, light
menstrual loss can occur in 5–10% of cases.
Endometrial ablation (EA)
EA aims to treat HMB by destroying the endometrium
(lining of the womb) which is responsible for heavy
periods. Historically, a number of methods have been
used to achieve this. Initially, in operations involving so
called ‘first-generation’ techniques, the interior of the
uterine cavity was visualised endoscopically and the
endometrial lining resected or ablated using electric dia-
thermy or laser energy. More recently, ‘second-gener-
ation’ techniques which did not require hysteroscopic
visualisation of the uterine cavity became popular.
Current second-generation procedures used in the UK
include thermal balloon EA and a bipolar radiofrequency
electrode EA device known as Novasure® (Hologic, Inc.).
Thermal balloon EA is undertaken by means of a sili-
cone balloon which is introduced through the cervix
into the uterine cavity. Hot fluid circulating within the
balloon ensures endometrial destruction and the
temperature and duration of treatment is carefully con-
trolled electronically by means of a computer attached
to the device. Novasure® uses radiofrequency energy de-
livered through an intrauterine mesh electrode which
expands on insertion through the cervix to fit the shape
of the uterine cavity. These EA techniques significantly
reduce menstrual loss and result in complete cessation
of bleeding in 40–50% of women [1]. Second-generation
EA procedures can be performed either under general or
local anaesthetic, costing the NHS £995 per procedure
carried out as a day case in 2011/2012 [12].
Identification and enrolment of potential participants
The consultant gynaecologist, dedicated research nurse
or designated team member at outpatient gynaecology
clinics and pre-assessment clinics in each recruiting
centre will identify all eligible women referred from pri-
mary care for consideration of surgery for HMB. As
local procedures at the participating hospitals are differ-
ent, the timing and mode of approach to women and
the consent process may vary in order to accommodate
both the specific circumstances at each site and the
needs of the women. The local recruitment team will
give or send a patient information leaflet (PIL) describ-
ing the study to each eligible woman who will have the
opportunity to discuss the study with her gynaecologist.
Women will also have the opportunity to discuss all as-
pects of the proposed research with the local clinical
team (staff at pre-admission clinics and ward staff while
admitted), the Research Nurse, family and friends and, if
appropriate, with their GP before admission. Women
may decide to participate during an initial consultation
with their gynaecologist, during a subsequent visit to
hospital (e.g. a clinic appointment, a pre-assessment visit
or when they are admitted for surgery) or alternatively
at home. If the woman agrees to be contacted at home
(recorded on the Surgical Assessment Form), she may
receive a telephone call from the local research nurse to
discuss any queries. Women who decide to participate
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following telephone counselling can either send their
completed documents (consent form and baseline ques-
tionnaire) through the post to the local team at their
treating hospital or bring it with them if they are return-
ing to hospital for another consultation or surgery.
The PIL and consent form refer to the possibility of
long-term follow-up to determine the incidence of
future operations (Additional file 1).
Randomisation and allocation
Eligible and consenting participants are randomised to
one of the two study groups in a 1:1 allocation ratio
using the randomisation application at the trial office at
the Centre for Healthcare Randomised Trials (CHaRT).
This randomisation application is available 24 h a day,
seven days a week as both an interactive voice response
(IVR) telephone system and as an Internet-based appli-
cation. The randomisation will use a minimisation algo-
rithm based on centre and age.
Follow-up procedures
Eligible patients who have provided signed informed con-
sent to participate in the study will complete the SF12,
Menorrhagia Multi-Attribute Quality of Life Scale
(MMAS) and EQ5D at baseline before being randomised
to either LASH or EA. They will also complete a diary for
days 1–14 post surgery, to record pain scores and the use
of analgesics. At six weeks after surgery, participants will
complete a questionnaire to measure Pain Numerical
Rating Scales (NRS), time to return to normal activities
and acceptability, EQ5D and SF12. At six months after
surgery and at 15 months following randomisation, partic-
ipants will complete the SF12, MMAS, EQ5D, satisfaction
with treatment and questions about healthcare utilisation.
Participants will receive up to two reminders by post,
email or phone, taking into account any preferences they
may have for mode of communication.
Change of status/withdrawal procedures
Participants will remain in the trial unless they chose to
withdraw consent or if they are unable to continue for a
clinical reason. If a participant withdraws consent, we will
not send them questionnaires but will seek permission for
the research team to continue to collect outcome data
from their healthcare records (via the case report forms
[CRFs]). All other changes in status—with the exception of
formal withdrawal of consent—will mean the participant is
still followed up for all study outcomes wherever possible.
Safety
The HEALTH trial involves procedures for the surgical
management of HMB in women which are well estab-
lished in clinical practice. Adverse effects may occur
during or after any type of surgery. In this trial, the
following events are potentially expected: admission to
high dependency unit/intensive care unit; emergency
hysterectomy; laparotomy; port site hernia; blood trans-
fusion; wound infection; lower urinary tract infection;
endometritis; blood-stained vaginal discharge; anaes-
thetic complications; low grade pyrexia; blood loss;
haematoma; constipation; pelvic discomfort/pain; in-
ternal bleeding or injury; pulmonary embolism (PE);
deep vein thrombosis (DVT); injury to the wall of the
uterus; bladder injury; bowel injury; ureteric injury; and
voiding dysfunction.
Outcome measures
This RCT will assess and compare LASH with standard
technique of EA in respect of: condition-specific QoL;
patient-reported satisfaction; and other patient-reported
outcomes (complications, recovery details, further
gynaecological surgery and modelled long-term cost-
effectiveness).
Primary outcome measure
The co-primary (clinical) outcomes will be: (1) MMAS,
a condition-specific QoL outcome [13] in the range of
0–100 based upon six domains, measured at 15 months
after randomisation; and (2) patient satisfaction, mea-
sured on a 6-point scale (from ‘totally satisfied’ to ‘totally
dissatisfied’) measured at 15 months after randomisa-
tion. Mean (SD) MMAS scores will be reported provided
the data are normally distributed. Satisfaction will be
treated as a binary variable: ‘totally satisfied’ vs other re-
sponses. We will address these two co-primary outcomes
in a hierarchical fashion. First, we will consider the pa-
tient satisfaction, and if this shows a statistically signifi-
cant difference (p < 0.05), then we will consider the
disease-specific QoL MMAS outcome. Both will need to
achieve statistical significance at p < 0.05 for the null hy-
pothesis to be rejected. By specifying this hierarchy, we
do not need to apply any adjustment for multiple com-
parisons, since the overall false-positive error is con-
trolled at an alpha of 0.05. Together these measures are
comprehensive, intuitive and accepted by patients and
the clinical community and have been used in previous
trials and studies by the Aberdeen group and others in
the field [14–16].
The primary economic outcome is the incremental
cost (to the health service) per quality-adjusted life year
(QALY) gained (LASH vs EA). We will calculate this
from within-trial health service costs (resource use col-
lected via CRFs and patient questionnaires, and valued
using standard unit prices) and generic QALYs (derived
from responses to the EQ-5D). We will derive the incre-
mental cost per QALY gained for LASH vs EA from
generalised linear regression models adjusting for base-
line health status and other important covariates.
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Secondary outcome measures
Patient-reported: MMAS score at six months after sur-
gery; patient-reported satisfaction at six months after
surgery; acceptability of procedure measured at six
weeks after surgery; severity of postoperative pain using
a pain NRS measured at 1–14 days and six weeks after
surgery; symptom diary days 1–14 after surgery (includ-
ing analgesic use); generic health-related QoL (SF-12,
EQ-5D 3-L) measured at six months after surgery and at
15 months after randomisation. We will describe out-
comes using mean (SD) or frequency (%) as appropriate.
Clinical: duration of operation; perioperative complica-
tions and recovery details including analgesia require-
ments; time to discharge; further gynaecological surgery
by 15 months after randomisation. We will describe out-
comes using mean (SD) or frequency (%) as appropriate.
Economic: wider societal costs associated with changes
in productivity based on information on the time taken to
return to normal activities (following intervention) com-
bined with questions on work productivity delivered dur-
ing the follow-up period. Furthermore, we will develop a
simple Markov model, based on within trial data supple-
mented by available published data on the requirement
for further gynaecological surgery over time (following the
alternative procedures) and use it to extrapolate cost-
effectiveness beyond 15 months after randomisation.
While the analyses within this application are based
upon an initial 15 months after randomisation follow-up,
we also anticipate collecting long-term information on
further gynaecological surgery by utilising Hospital
Episode Statistics for England and Wales and Information
Services Division (ISD) data for Scotland. We will use
these data in the future to revise the extrapolated longer-
term estimates of cost-effectiveness for LASH vs EA.
Schedule of data collection
The components of follow-up are shown in Table 1.
Sample size, proposed recruitment rate and
milestones
Sample size
The specification of the target difference was driven by
two criteria: (1) what target difference would be import-
ant if it existed; and (2) what would be a realistic differ-
ence [17] given the interventions under evaluation. With
regards to (2), the observed rates in the recent IPD
meta-analysis of abdominal hysterectomy vs first-
generation EA [6] would lead to a target difference of
odds ratio (OR) of 2.84 (95% vs 87%) for patient satisfac-
tion. Such an OR also equates to a medium-sized
standardised effect (Cohen’s d). This requires 292 partic-
ipants per group for a two-sided test with 90% power.
This size would also be more than sufficient to allow a
small- to medium-sized (0.3, Cohen’s d) standardised ef-
fect in the co-primary outcome, MMAS, to be detected;
this is a target difference for MMAS that can be viewed
as important and has observed in other areas for similar
outcomes. This would equate to being able to detect a
target difference of 10 points on the 0–100 scale, given a
standard deviation of 33 points or less. Given these as-
sumptions for the co-primary outcomes, and additionally
allowing for 10% missing data, 648 participants in total
are required.
Recruitment rates and milestones
The original recruitment projection was based on 30 ac-
tive centres participating, with the expectation that they
would contribute a minimum of 26 women per centre
over 21 months of recruitment (months 6–26 inclusive).
We expected a staggered recruitment of centres with all
centres active by the end of month 12. Recruitment at
all sites was projected to be 50% of the projected
monthly total in the first month and reduced recruit-
ment in the peak holiday months of August and
December.
Table 1 HEALTH measurement of outcomes: components and timing
Pre randomisation Post surgery Post randomisation
Baseline Surgery Days 1–14 6 weeks 6 months 15 months
Baseline CRF X
Surgical details X
Pain NRS symptom diary X
Pain NRS X
Time to return to normal activities X
Acceptability X
Satisfaction X X
MMAS, X X X
EQ-5D 3-L, SF-12 X X X X
Healthcare utilisation X X
Participant costs X
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Revised recruitment rates and milestones
At steady state, the recruitment rate was assumed to be
approximately 62 women per month, although recruit-
ment was actually slower than anticipated. This occurred
for a number of reasons, principally patient preference,
lack of equipoise among clinical colleagues and organisa-
tional issues at the recruiting centres.
The revised projections for the extension period are
based on a conservative estimate of the recruitment
trend observed over a six-month period from September
2015 to February 2016 inclusive, resulting in an expected
recruitment rate of 25 participants per month. As a re-
sult, a 12-month extension to the recruitment phase is
necessary to achieve the original target sample size (648
participants in total).
The original and revised recruitment projections can
be found in Fig. 2 and the revised project timetable and
milestones are shown in the Gantt chart in Fig. 3.
Statistical analysis
We will base all analyses on the intention-to-treat
principle, analysing women in the groups to which they
are randomised. We will conduct all study analyses ac-
cording to a statistical analysis plan agreed in advance
by the Trial Steering Committee. We will conduct the
analyses at two-sided 5% significance level with corre-
sponding 95% confidence interval generated as appropri-
ate. Full details may be found in the separate statistical
analysis plan.
We will conduct the analysis of the two co-primary
outcomes (patient satisfaction and MMAS) independ-
ently. We will analyse patient satisfaction (‘totally satis-
fied’ vs others) using a logistic regression model with
adjustment for minimisation factors. We will use a
complete-case analysis for the main analyses, with no
imputation for missing data. Sensitivity analyses will as-
sess the impact of varying the dichotomisation cut-off
and adjusting for clustering at centre and surgeon levels.
Sensitivity analyses (such as using a multiple imputation
approach) will also explore what influence missing data
might have on the robustness of our findings and where
feasible modelling non-ignorable (informative) missing
data mechanisms. A further analysis of patient satisfac-
tion will use a proportional odds model utilising the
underlying ordinal (Likert) scale (Ologit function, Stata-
corp, 2012). We will analyse the MMAS using linear re-
gression adjusted for baseline and minimisation factors
or an ordinal model if the data are found to be skewed.
We will analyse secondary outcomes using generalised
linear models adjusted for minimisation factors (and,
when appropriate, a baseline measure).
Planned subgroup analyses
We will perform exploratory subgroup analyses for the
following groups: uterine cavity length (8 cm ≤ vs > 8 cm);
menstrual pain (dysmenorrhoea) at baseline (‘severe’ vs
non-‘severe’ – determined using a 5-point Likert scale); fi-
broids (present or absent); patient age < 40 or > 40 years.
We will conduct the pre-specified subgroup analyses by
including the corresponding treatment by subgroup inter-
action term in the corresponding regression models for
the co-primary outcomes (patient satisfaction and
MMAS). No other subgroup analyses are planned. We will
state the subgroup analyses as exploratory and evaluate at
the 5% two-sided significance level.
Proposed frequency of analyses
We will perform a single statistical analysis when 12-
month follow-up data have been collected. An independ-
ent Data Monitoring Committee will review confidential
interim analyses of accumulating data at its discretion
but at least annually.
Fig. 2 Recruitment projections
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Economic evaluation
The economic analysis will consist of a trial based ana-
lysis of individual patient level cost and effect (QALY)
data and a decision modelling component to inform
cost-effectiveness in the longer term.
For the within-trial analysis, we will estimate total costs
to the health service, wider costs to society associated with
lost productivity and QALYs for each individual patient en-
rolled in the RCT. We will estimate costs of the initial
intervention procedures from resource use data recorded
on the CRFs of each individual patient (including time in
theatre, staff present, any perioperative complications and
length of stay in hospital post treatment) coupled with rou-
tine unit cost data [12, 18]. We will also value any subse-
quent contacts with primary and secondary care (collected
from patient questionnaires at six months after surgery
and 15 months after randomisation), for each patient using
nationally accepted sources of unit costs. Since the EQ-5D
is the recommended instrument for deriving QALY
weights by NICE (https://www.nice.org.uk/process/pmg9/
chapter/foreword), we will use participant responses to this
instrument (at baseline, six weeks and six months after sur-
gery and 15 months after randomisation) to derive QALYs.
The SF-12 is being included as another potentially more
sensitive measure of general health-related QoL and will
provide an alternative means for estimating QALYs via the
SF-6D scoring algorithm. We will undertake this as a sensi-
tivity analysis at 12 months. Productivity losses will be esti-
mated based on the reported time taken to return to
normal activities (assessed at six weeks after surgery) and
responses to work productivity questions at six months
after surgery and 15 months after randomisation. We will
value time lost from paid employment using national age-/
sex-specific average gross wage rates [19]. We will estimate
the value of time lost from alternative non-paid activities
using appropriate shadow prices.
Analysis of the patient level cost and QALY data will
use appropriately specified generalised linear regression
models adjusted for baseline EQ-5D score and minimisa-
tion factors applied during randomisation [20]. From these
analysis models, the co-efficient for the treatment alloca-
tion group will provide estimates of the incremental costs
and QALYs associated with LASH vs EA. We will charac-
terise uncertainty surrounding the joint estimates of incre-
mental costs and effects by running the regression models
on a large number of bootstrapped samples obtained, with
replacement, from the original trial sample. This process
will generate a large number of estimates of the incremen-
tal costs and effects, capturing any correlation between
them. We will plot these results on the incremental cost-
effectiveness plane and use them to derive a cost-
effectiveness acceptability curve, indicating the probability
of LASH being cost-effective (at 12 months) given dif-
ferent notional values of decision-makers’ willingness
to pay per QALY gained. The primary analysis will as-
sess cost-effectiveness from the health service perspec-
tive, but we will also conduct a secondary analysis
incorporating wider costs to society. As a further step
to help present the 12-month findings in a meaningful
way for decision-makers, we will present all costs and
outcomes within a cost–consequence balance sheet.
This will summarise all the costs and trial outcomes by
treatment allocation group and indicate which treat-
ment group each outcome favours.
Fig. 3 HEALTH Gantt
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While the within-trial analysis will be useful for
informing cost-effectiveness in the short term, previous
research suggests that a longer time horizon may be re-
quired to determine the relative cost-effectiveness of
LASH vs EA [8], as a result of EA being less costly and
effective in the short term but associated with higher
failure rates and subsequent surgery beyond 12 months.
Therefore, we will develop a simple Markov model to
simulate the recurrence of symptoms and need for sub-
sequent treatment over time, in order to estimate cost-
effectiveness in the longer term. We will construct the
model in consultation with clinicians and based on a
review of existing decision models developed in the
field. Input parameters will initially be informed by the
within-trial analysis (to determine initial treatment
costs and outcomes and the probability of any subse-
quent treatment events/complications occurring within
12 months). This will be supplemented with published
data on recurrence and the need for further gynaeco-
logical surgery (repeat EA, LASH or conventional total
hysterectomy) following EA and LASH. The model will
incorporate the initial health service costs of treatment,
ongoing costs associated with successful and unsuc-
cessful treatment, and costs associated with subsequent
surgery. We will apply utility weights (obtained from
the trial data) to the alternative states in the model,
allowing modelled QALYs to be estimated. We will run
the model over a five-year period (the time point by
which most women would be expected to have com-
pleted any subsequent required treatment), though we
will also explore the impact of adopting longer time ho-
rizons. Linkage of participants’ records to health epi-
sode statistics will allow future quantification of the
incidence of repeat gynaecological surgery, providing a
means for validating/updating initial model based
predictions.
We will carry out probabilistic and deterministic sensi-
tivity analysis to characterise the uncertainty surround-
ing the model based estimates of incremental costs and
effects of LASH vs EA. For the Probabilistic Sensitivity
Analysis (PSA), we will assign an appropriate distribu-
tion to each model input parameter (reflecting the de-
gree of uncertainty surrounding it due to sampling
variation) and we will analyse the model a large number
of times, each time randomly drawing a value for each
input parameter from its assigned distribution [21]. This
process will generate a large number of estimates of the
incremental costs and effects. We will use cost-
effectiveness acceptability curves to summarise the find-
ings from the PSA. Further deterministic analysis will as-
sess the sensitivity of the model based estimates to
further choices over sources of parameter estimates and
any structural assumptions required when constructing
the model.
Research governance, data protection and
sponsorship
Research governance
The trial is under the auspices of CHaRT based at the
Health Services Research Unit (HSRU), University of
Aberdeen. This will ensure compliance with Research
Governance and provide centralised trial administration,
database support, and economic and statistical analyses.
CHaRT is a registered Clinical Trials Unit with particu-
lar expertise in running multicentre RCTs of complex
and surgical interventions.
The two Aberdeen-based co-Chief Investigators will en-
sure, through the Trial Steering Committee (TSC), that ad-
equate systems are in place for monitoring the quality of
the study (compliance with the principles of Good Clinical
Practice) and appropriate expedited and routine reports,
to a level appropriate to the risk assessment of the study.
Data protection
We will ensure that data collected during the course of
the research is handled confidentially and accessed only
by members of the trial team. We will store participants’
details on a secure database under the guidelines of the
1988 Data Protection Act and regular checks and moni-
toring are in place to ensure compliance. Data are stored
securely in accordance with the Act and archived to a se-
cure data storage facility. The senior IT manager (in col-
laboration with the Chief Investigator) will manage access
rights to the dataset. We will allocate participants an indi-
vidual specific trial number and we will anonymise their
details on the secure database. We anticipate that anon-
ymised trial data may be shared with other researchers to
enable international prospective meta-analyses. To comply
with the fifth Principle of the Data Protection Act 1998,
personal data will not be kept for longer than is required
for the purpose for which it has been acquired.
Data handling, record keeping and archiving
The local investigator and/or research nurse working in
each hospital site will enter clinical data into the data-
base, together with data from questionnaires completed
at clinic. Staff in the trial office will enter data collected
on questionnaires returned by post to the trial office.
Staff in the trial office will also work closely with local
research nurses to ensure that the data are as complete
and accurate as possible. Extensive range and
consistency checks will further enhance the quality of
the data.
Discussion
The HEALTH trial is the largest ever randomised con-
trolled trial of alternative surgical treatments for women
with HMB eligible for EA. It is designed to test the
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hypothesis that LASH is superior to second-generation
EA in terms of patient satisfaction, QoL and costs.
Since the trial was first designed there have been
several modifications to the protocol, none of which
would have had a significant impact on the trial de-
sign and conduct. The key modifications include a
change to the timing at which the final questionnaire
(which captures the primary outcome) is triggered
(12 months post surgery to 15 months post random-
isation) and changes to the exclusion criteria where
‘previous endometrial ablation’ and ‘abnormal cytology’
were added and ‘submucous fibroids distorting the
uterine cavity’ was changed to ‘any fibroids > 3 cm dis-
torting the uterine cavity’. However, both these changes
were made early in the trial.
The key practical challenges of this trial have been par-
ticipant recruitment and retention. Early in the recruit-
ment period, we noted issues with patient preference,
which was heightened by the fact that LASH was being
offered in some centres as part of the normal care path-
way. Several strategies have been adopted to address
these issues which have included increased engagement
with the participating centres (regular updates, newslet-
ters, research nurse teleconferences), reiterating the im-
portance of the clinical question including explaining to
practitioners that LASH is not endorsed by current
NICE guidelines and opening further centres using spe-
cific criteria to identify those with a strong interest in
the clinical question.
Strategies adopted to ensure response rates to the pos-
tal questionnaires remained within expected levels in-
cluded a newsletter which pre-notified the participants
of the questionnaire delivery (primary outcome only),
the option to complete the questionnaire online and
monetary incentives (unconditional £25 gift voucher for
UK high street stores). The full impact of the strategies
to improve recruitment and retention will be discussed
in the full trial report.
Trial status
The first participant was randomised into the trial on
21st May 2014 and the trial is currently open to recruit-
ment in 33 UK centres, with the last participant follow-
up expected in May 2018.
HEALTH protocol Version 1.9: 1st November 2016
End notes
Safety
The HEALTH trial involves procedures for the surgical
management of HMB in women which are well estab-
lished in clinical practice. Adverse effects may occur
during or after any type of surgery.
Definitions
An adverse event (AE) is any untoward medical event
affecting a clinical trial participant. Each initial AE will
be considered for severity, causality or expectedness
and may be reclassified as a serious event or reaction
based on prevailing circumstances.
A serious adverse event (SAE), is any AE, that:
 results in death;
 is life-threatening (i.e. the individual was at risk of
death at the time of the event; it does not refer to an
event which hypothetically might have caused death
if it were more severe);
 requires hospitalisation or prolongation of existing
hospitalisation;
 results in persistent or significant disability or
incapacity;
 is otherwise considered medically significant by the
investigator.
Note: Hospitalisations for treatment planned before
randomisation and hospitalisation for elective treatment
of a pre-existing condition will not be considered as an
AE. Complications occurring during such hospitalisation
will be AEs or SAEs as appropriate.
HEALTH-specific expected adverse events
In this trial the following AEs are potentially expected:
admission to HTU/ITU; emergency hysterectomy;
laparotomy; port site hernia; blood transfusion; wound
infection; lower urinary tract infection; endometritis;
blood-stained vaginal discharge; anaesthetic complica-
tions; low grade pyrexia; blood loss; haematoma; consti-
pation; pelvic discomfort/pain; internal bleeding or
injury; PE; DVT; injury to the wall of the uterus; blad-
der injury; bowel injury; ureteric injury; and voiding
dysfunction.
Procedures for detecting, recording, evaluating and
reporting AEs and SAEs
Detecting AEs and SAEs
Non-serious events will be recorded in the CRFs.
Planned primary care or hospital visits for conditions
other than those associated with HMB or consequence
of surgery will not be collected or reported. Hospital
visits (planned or unplanned) associated with further in-
terventions due to HMB (e.g. further surgery) will be re-
corded as an outcome measure, but will not be reported
as SAEs.
Any SAEs related to the participants’ HMB treatment
that are not further interventions (e.g. if a participant is
admitted to hospital for treatment of infection) will be
recorded on the SAE form. In addition, all deaths for
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any cause (related or otherwise) will be recorded on the
SAE form.
Within HEALTH, ‘relatedness’ is defined as an event
that occurs as a result of a procedure required by the
protocol, whether or not it is either: (1) the specific
intervention under investigation; or (2) it is administered
outside the study as part of normal care.
Recording AEs and SAEs
Depending on severity, when an AE/SAE occurs, it is
the responsibility of the Investigator (or delegate) to re-
view appropriate documentation (e.g. hospital notes, la-
boratory and diagnostic reports) related to the event.
The Investigator (or delegate) should then record all
relevant information in the CRF and on the SAE form.
Information to be collected includes dose, type of
event, onset date, Investigator assessment of severity and
causality, date of resolution as well as treatment re-
quired, investigations needed and outcome.
Evaluating AEs and SAEs
All AEs will be assessed in respect of seriousness, rela-
tionship to study intervention, whether expected or un-
expected and, therefore, whether constituting a SAE by
the local PI, CI or their deputies.
Assessment of seriousness
The Investigator should make an assessment of serious-
ness as defined above in ‘Definitions’.
Assessment of causality
The Investigator must make an assessment of whether
the AE/SAE is likely to be related to any of the research
procedures according to the following definitions:
 Related: resulted from administration of any of the
research procedures;
 Unrelated: where an event is not considered to be
related to any of the research procedures.
Alternative causes such as natural history of the
underlying disease, concomitant therapy, other risk fac-
tors and the temporal relationship of the event to the
treatment should be considered.
Assessment of expectedness
When assessing expectedness refer to the expected events.
Reporting AEs and SAEs
Reporting responsibilities of the CI When an SAE
form is uploaded onto the trial website, the Trial Man-
ager will be automatically notified. If, in the opinion of
the local PI and the CI, the event is confirmed as being
serious and related and unexpected, the CI or Trial
Manager will notify the sponsor within 24 h of receiving
the signed SAE notification. The sponsor will provide an
assessment of the SAE.
The CI (or Trial Manager) will report any related and
unexpected SAEs to the main REC within 15 days of the
CI becoming aware of it. All related SAEs will be sum-
marised and reported to the Ethics Committee, the
Funder and the Trial Steering Committee in their regu-
lar progress reports.
If all the required information is not available at the time
of reporting, the Investigator must ensure that any missing
information is provided as soon as this becomes available.
It should be indicated on the report that this information
is follow-up information of a previously reported event.
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